OUR UNIQUE APPROACH

Over 300 million people worldwide suffer from chronic inflammatory diseases. There is a large unmet need for treatments for chronic inflammatory disease that are efficacious and safe. Xalud Therapeutics is developing a non-viral gene therapy targeting immune modulation. Our mission is to harness the power of interleukin-10 (IL-10), a potent anti-inflammatory cytokine, to address the root cause of inflammation and subsequently restore homeostasis in the immune system.

AN UPSTREAM TREATMENT FOR
CHRONIC INFLAMMATION THAT
RESTORES BALANCE TO THE

IMMUNE SYSTEM

OUR SCIENCE

A healthy, strong body lives in a state of equilibrium. Every day, it detects potential signals of injury or chronic disease progression and naturally restores itself by finely balancing anti-inflammatory cytokines and pro-inflammatory mediators. Unfortunately when the body's immune system is unbalanced, inflammation can flare and persist over long periods of time. This results in a myriad of diseases and associated symptoms, including chronic, debilitating pain that prevents millions of people from living healthy productive lives.

Xalud Therapeutics aims to break this cycle of chronic, pathologic inflammation. Instead of masking symptoms like traditional pain drugs, we help the body to restore the critical balance of inflammatory and restorative pathways by adding back one of the body's own natural defenses to increase important anti-inflammatory signals.

OUR PLATFORM

IL-10 is a potent anti-inflammatory cytokine that inhibits and
counterbalances the effects of inflammatory cytokines. Insufficient IL-10 expression or signaling have been implicated in inflammation and numerous immune disease states. Our breakthrough lead therapeutic candidate, XT-150, combats pathologic inflammation locally through expression of IL-10v, a proprietary modified variant of IL-10. Xalud is currently evaluating XT- 150 across multiple treatment indications in preclinical and clinical studies.